CoChat

Lixisenatide as add‐on to oral anti‐diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes

Open access
Raccah, Denis, Gourdy, Pierre, Sagnard, Luc, Ceriello, Antonio · 2014 · Diabetes/Metabolism Research and Reviews
Cited by 14

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background: Achieving recommended glycated haemoglobin (HbA 1c) targets in patients with type 2 diabetes mellitus (T2DM) requires effective control of fasting and post‐prandial plasma glucose. As T2DM progresses, oral anti‐diabetics are no longer sufficient to maintain glycaemic control. Five phase III studies in the GetGoal clinical trial programme assessed the efficacy of lixisenatide, a once‐daily prandial glucagon‐like peptide‐1 receptor agonist, in combination with oral anti‐diabetics in patients with T2DM insufficiently controlled using oral anti‐diabetics. Methods: A meta‐analysis was performed of the results of five 24‐week clinical trials (comprising 2760 patients) concerning lixisenatide or placebo plus oral anti‐diabetic therapy. The primary endpoint of these studies was change in HbA 1c at week 24. Changes in fasting and post‐prandial plasma glucose, and weight were also established as were the odds ratios for hypoglycaemia and composite safety and efficacy endpoints. Meta‐analysis outcomes were assessed using a random effects model. All meta‐analyses were performed using RevMan, version 5.1. Results: Lixisenatide was significantly better than placebo in terms of achieving all endpoints in this meta‐analysis, including the primary endpoint change in HbA 1c at week 24, with p < 0.0001 for all endpoints. The mean number of symptomatic hypoglycaemic events per patient year was increased for patients in the lixisenatide versus placebo groups (p = 0.04). However, compared with patients in the placebo group, patients treated with lixisenatide were more likely to achieve composite efficacy and safety endpoints. Conclusions: This meta‐analysis demonstrates that lixisenatide in combination with oral anti‐diabetic therapy significantly improves outcomes combining efficacy and safety parameters in patients with T2DM. © 2014 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.2548

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 14

Metadata

Authors
Raccah, D., Gourdy, P., Sagnard, L., & Ceriello, A.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2014-11
Volume
30
Issue
8
Pages
742-748
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W1537288704
Cited by
14
References
12
FWCI
2.15
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.